No Data
Tiantan Biotech 2024 Annual Report
Summary of Tiantan Biotech\'s 2024 Annual Report
Beijing Tiantan Biological Products Corporation (600161.SH): In 2024, the net income is 1.549 billion yuan, an increase of 39.58% year-on-year.
Gelonghui, March 28 – Beijing Tiantan Biological Products Corporation (600161.SH) announced the 2024 annual report, reporting revenue of 6.032 billion yuan, a year-on-year increase of 16.44%; Net income attributable to the shareholders of the listed company was 1.549 billion yuan, a year-on-year increase of 39.58%; Basic EPS was 0.78 yuan. A cash dividend of 1 yuan (tax included) is proposed to be distributed to all shareholders for every 10 shares.
Beijing Tiantan Biological Products Corporation (600161.SH): Subsidiary company has once again obtained the "High-tech Enterprise Certificate".
On March 24, Glor Capital reported that Beijing Tiantan Biological Products Corporation (600161.SH) announced that its subsidiary, China National Pharmaceutical Group Guizhou Biological Pharmaceutical Co., Ltd. (referred to as "Guizhou Blood Products"), recently received the "High-tech Enterprise Certificate" jointly issued by the Guizhou Provincial Department of Science and Technology, Guizhou Provincial Department of Finance, and the State Taxation Administration Guizhou Provincial Taxation Bureau. The certificate number is GR202452000126, issued on December 9, 2024, and is valid for three years. This award of the "High-tech Enterprise Certificate" for Guizhou Blood Products is a re-recognition following the expiration of the original certificate.
Beijing Tiantan Biological Products Corporation (600161.SH): The holding subsidiary has obtained the GMP certificate from Turkey.
On January 22, Gelonghui reported that Beijing Tiantan Biological Products Corporation (600161.SH) announced that its holding subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. recently received a GMP certificate issued by the Turkish Ministry of Health's Medicines and Medical Instruments Authority. The GMP certification pertains to the intravenous human immunoglobulin production line located in the Chengdu Rongsheng blood products manufacturing workshop, which has a designed processing capacity of 1,200 tons per year.
Tiantan Biotech: Tiantan Biotech 2024 Annual Performance Report Announcement
